Cambium Bio (ASX:CMB) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Cambium Bio's annualized Gross Profit for the quarter that ended in Dec. 2023 was A$0.00 Mil. Cambium Bio's average Total Assets over the quarter that ended in Dec. 2023 was A$1.28 Mil. Therefore, Cambium Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Cambium Bio Gross-Profit-to-Asset % Historical Data

The historical data trend for Cambium Bio's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Gross-Profit-to-Asset % Chart

Cambium Bio Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

54.47

180.33

Cambium Bio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															0.83	-	-	-	-

Competitive Comparison of Cambium Bio's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Cambium Bio's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Gross-Profit-to-Asset % falls into.

Cambium Bio Gross-Profit-to-Asset % Calculation

Cambium Bio's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	0	/	( (2.555	+	2.464)	/ 2 )
	=	0	/	2.5095
	=	0.00 %

Cambium Bio's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (2.464	+	0.089)	/ 2 )
	=	0	/	1.2765
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Cambium Bio Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cambium Bio (ASX:CMB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021

Website

https://www.regeneus.com.au

Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio (ASX:CMB) Headlines

No Headlines